Composition as well as preparation method and application thereof in protecting brain health

Abstract

The invention belongs to the technical field of nutritional compositions, and particularly relates to a composition, a preparation method thereof and application of the composition in protecting brain health. The composition provided by the invention is prepared from docosahexaenoic acid, 3-sialic acid lactose and phosphatidylserine. The composition is clear in sleep improvement effect, can effectively solve the problem of sleep maintenance caused by sleep deprivation, has the effects of protecting neural functions, improving memory and relieving anxiety from multiple dimensions, and can repair brain tissue damage and protect brain health. Based on the composition, products for assisting in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health and improving concentration can be developed, the health requirements of different people are comprehensively met, and the application value is high.

Description

Technical Field

[0001] This invention belongs to the field of nutritional composition technology, specifically relating to a composition, its preparation method, and its application in protecting brain health. Background Technology

[0002] With the fast pace of modern life, increased work pressure, and the influence of unhealthy lifestyle habits, sleep disorders are becoming increasingly common, with sleep deprivation being a significant factor affecting public health. Sleep deprivation not only directly leads to difficulty maintaining sleep and decreased sleep quality, but also further causes damage to neurological functions, such as memory decline (including multi-dimensional memory impairments such as spatial memory, short-term memory, and working memory), frequent anxiety-like behaviors, and in the long term, even pathological damage to brain tissue (such as neuronal disorder, loss, and pyknosis), seriously threatening human brain health and overall physiological function.

[0003] To address the aforementioned issues, while various products exist on the market for improving sleep and protecting nerves, they generally suffer from numerous technical deficiencies: First, most products rely on a single active ingredient to function; however, the effect of a single ingredient is limited and cannot simultaneously address the multi-dimensional problems caused by sleep deprivation, such as sleep disorders, nerve function damage, and brain tissue damage. Second, the ingredient ratios of existing products lack scientific basis and have not been optimized to meet the core needs of sleep deprivation and brain health protection, making it difficult to precisely target pathological mechanisms and achieve the dual high-efficiency effects of improving sleep and protecting nerves.

[0004] Patent CN119730733A provides a kit for a nutrient blend composition, the kit comprising at least two of the following compositions: a) nutrient blend composition A, which contains at least three components selected from: vitamin B1, vitamin B2, vitamin B6, zinc, iron, copper, histidine, isoleucine, lysine, leucine, vitamin A, folic acid, magnesium, phosphorus, potassium, selenium, 3'-SL, alanine, cystine, glutamic acid, phenylalanine, proline, serine, threonine, tyrosine, and valine; b) nutrient blend composition B, which contains at least three components selected from: DPA, ARA, sphingomyelin, phosphatidylcholine, octadecanoic acid, fructooligosaccharides, and 6'-SL. -SL, stearatetraenoic acid, β-cryptoxanthin, α-lactalbumin, gangliosides, phosphatidylinositol, 3'-SL, eicosapentaenoic acid; c) nutrient blend composition C, wherein the nutrient blend composition C comprises at least three components selected from the following: DHA, sphingomyelin, phosphatidylcholine, histidine, isoleucine, leucine, valine, α-carotene, folic acid, α-lactalbumin, gangliosides, phosphatidylinositol, phosphatidylethanolamine, eicosapentaenoic acid, stearatetraenoic acid, DPA, 3'-SL, 6'-SL, alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, α-tocopherol, octadecanoic acid, eicosapentaenoic acid, phosphorus, phosphatidylserine. The kit of this nutrient blend is specifically designed to promote myelination in target brain regions, particularly the social brain, in children at specific ages and stages of brain development.

[0005] The core design objective of this patent is to "promote myelination in target brain regions of children at specific ages and stages of brain development," focusing solely on the myelination process during children's brain development. It does not address the critical health issue of "sleep disorders," nor does it address the cascading problems caused by sleep deprivation (such as difficulty maintaining sleep, memory impairment, anxiety, and pathological damage to brain tissue). In contrast, the core need of this invention is to solve the multidimensional health problems caused by sleep deprivation. The significant difference in objectives means that this patented kit cannot meet the needs of individuals experiencing neurological dysfunction and decreased sleep quality due to sleep deprivation. Its application is limited to assisting children's brain development and cannot cover a broader range of individuals with sleep and brain health needs (such as adults with sleep disorders and those experiencing anxiety).

[0006] Therefore, developing a composition with scientifically formulated ingredients in reasonable proportions that can synergistically improve sleep and protect brain health, and which is easy to prepare and has a wide range of applications, has become a key issue that urgently needs to be addressed in the field of nutritional composition technology. It has important practical significance and application value for improving sleep quality, protecting nerve function, and maintaining brain health. Summary of the Invention

[0007] To address the above shortcomings, the present invention provides a composition, a method for preparing the same, and its application in protecting brain health.

[0008] The technical solution of the present invention includes: On one hand, the present invention provides a composition comprising docosahexaenoic acid, 3-sialyl lactose and phosphatidylserine.

[0009] Specifically, the weight ratio of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in the composition is 1.5-2.5:0.8-2.2:0.1-1.

[0010] Preferably, the weight ratio of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in the composition is 1.5-1.6, 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2.0, 2.0-2.1, 2.1-2.2, 2.2-2.3, 2.3-2.4, or 2.4-2.5: 0.8-0.9, 0.9-1.0, 1.0-1.1, 1.1-1.2, 1 0.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6, 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2.0, 2.0-2.1 or 2.1-2.2; 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9 or 0.9-1.0.

[0011] More preferably, the weight ratio of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in the composition is 2:1.0-1.1, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6, 1.6-1.7, 1.7-1.8, 1.8-1.9, or 1.9-2.0:0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, or 0.9-1.0.

[0012] More preferably, the weight ratio of docosahexaenoic acid, 3-sialyl lactose and phosphatidylserine in the composition is 2:1.5:0.55.

[0013] In another aspect, the present invention provides a method for preparing the composition described in any of the preceding claims, the method comprising mixing docosahexaenoic acid, 3-sialyl lactose and phosphatidylserine uniformly to obtain the composition.

[0014] In another aspect, the present invention provides a food product, characterized in that the food product comprises the composition described in any one of the preceding claims.

[0015] Specifically, the food also includes nutritionally acceptable nutritional additives.

[0016] Preferably, the nutritional additives include, but are not limited to, any one or more of the following: dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0017] Specifically, the dosage form of the food includes solid dosage form, semi-solid dosage form, or liquid dosage form.

[0018] Preferably, the food products include, but are not limited to: candy, soy milk, yogurt, canned food, biscuits, chocolate, pastries, cream, cheese, dairy products, milk powder, formula milk powder, ice cream, jam, fruit puree, candied fruit, preserved fruit, dried fruit, bread, egg rolls, protein drinks, solid beverages, lactic acid bacteria drinks, plant protein drinks, carbonated drinks, coffee, or puffed foods.

[0019] Preferably, the food includes human food or animal food.

[0020] In another aspect, the present invention provides a health product, characterized in that the health product comprises the composition described in any one of the above claims.

[0021] Preferably, the health product further includes any one or more of the following: plant extracts, animal extracts, vitamins, bioactive peptides, enzymes, acids, polysaccharides, or minerals.

[0022] Specifically, the dosage forms of the health products include solid dosage forms, semi-solid dosage forms, or liquid dosage forms.

[0023] Preferably, the dosage form of the health product includes, but is not limited to: tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids, or drops.

[0024] In another aspect, the present invention provides the use of the composition described in any one of the above claims in the preparation of a product, said product comprising any one or more of the following: (1) Foods, health products, or medicines that help improve memory; (2) Medications for the prevention, treatment, or adjunctive treatment of insomnia; (3) Medications for the prevention, treatment, or adjunctive treatment of anxiety; (4) Medications for regulating neurodevelopmental disorders; (5) Medicines that protect brain health.

[0025] (6) Medications to improve concentration.

[0026] In another aspect, the present invention provides a medicine comprising the composition described in any of the preceding claims.

[0027] Specifically, the dosage forms of the medicine include gastrointestinal dosage forms and non-gastrointestinal dosage forms.

[0028] Preferably, the dosage form of the medicine includes, but is not limited to, any one or more of the following: tablets, pills, powders, suspensions, gels, emulsions, creams, granules, capsules, suppositories, injections, sprays, and injections.

[0029] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0030] Preferably, the pharmaceutically acceptable excipients include one or more of the following: wetting agents, emulsifiers, preservatives, antioxidants, buffers, diluents, lubricants, solutes, suspending agents, solubilizers, thickeners, stabilizers, sweeteners, and flavorings.

[0031] In another aspect, the present invention provides a method for assisting in improving memory, the method comprising using any of the compositions, foods, health products or pharmaceuticals described above.

[0032] Specifically, the method includes administering an effective amount of the composition, food, health product, or medicine to the subject.

[0033] Preferably, the subject is a mammal.

[0034] More preferably, the mammal is a human.

[0035] In another aspect, the present invention provides a method for preventing, treating, or adjunctive treating insomnia, the method comprising using any of the compositions or pharmaceuticals described above.

[0036] Specifically, the method includes administering an effective amount of the composition or drug to the subject.

[0037] Preferably, the subject is a mammal.

[0038] More preferably, the mammal is a human.

[0039] In another aspect, the present invention provides a method for preventing, treating, or assisting in the treatment of anxiety, the method comprising using any of the compositions or medicines described above.

[0040] Specifically, the method includes administering an effective amount of the composition or drug to the subject.

[0041] Preferably, the subject is a mammal.

[0042] More preferably, the mammal is a human.

[0043] In another aspect, the present invention provides a method for regulating neurodevelopmental disorders or protecting brain health, the method comprising using any of the compositions or pharmaceuticals described above.

[0044] Specifically, the method includes administering an effective amount of the composition or drug to the subject.

[0045] Preferably, the subject is a mammal.

[0046] More preferably, the mammal is a human.

[0047] In another aspect, the present invention provides a method for improving concentration, the method comprising using any of the compositions or pharmaceuticals described above.

[0048] Specifically, the method includes administering an effective amount of the composition or drug to the subject.

[0049] Preferably, the subject is a mammal.

[0050] More preferably, the mammal is a human.

[0051] The beneficial effects of this invention are: The composition provided by this invention has a clear effect on improving sleep, effectively solving sleep maintenance problems caused by sleep deprivation, protecting nerve function from multiple dimensions, improving memory and relieving anxiety. The composition can repair brain tissue damage and protect brain health. Based on this composition, products can be developed to assist in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health, and improving concentration, comprehensively covering the health needs of different populations and possessing high application value. Attached Figure Description

[0052] Figure 1 Design protocols for animal experiments.

[0053] Figure 2 The figure shows the effect of the composition on improving sleep status in sleep-deprived mice; * represents P<0.05, ** represents P<0.01, *** represents P<0.001, **** represents P<0.0001, and ns represents not significant.

[0054] Figure 3 The figures show the results of the Barnes maze experiment; * represents P<0.05, *** represents P<0.001, and **** represents P<0.0001.

[0055] Figure 4The figure shows the ameliorative effect of sleep deprivation on anxiety-like behavior in mice; A represents total movement distance; B represents rest time; C represents the proportion of distance in the central region; * represents P<0.05, ** represents P<0.01, and ns represents not significant.

[0056] Figure 5 The effect of the composition on improving concentration is shown in the figure; **** in the figure represents P<0.0001. Detailed Implementation

[0057] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0058] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0059] This invention used SPF-grade male C57BL / 6J mice (8 weeks old, 20-25 grams), purchased from Shaanxi Nuoyou Biotechnology Co., Ltd. All experimental procedures followed the "Guidelines for the Protection and Use of Laboratory Animals (8th Edition)" (ISBN-10:0-309-15396-4), and the animal procedures were approved by the Animal Ethics Committee of Northwest A&F University. The mice were housed in the SPF-grade animal room of the Experimental Animal Center of Northwest A&F University (temperature: 25±2 ℃, humidity: 50%±15%, 12 / 12 h light cycle, fed standard feed: AIN-93G daily, purchased from Jiangsu Xietong Pharmaceutical Biotechnology Co., Ltd., with free access to water).

[0060] Example 1 A composition A composition comprising docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine, wherein the weight ratio of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine is 2:1.5:0.55.

[0061] Example 2 A composition A composition comprising docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in a weight ratio of 2:2:1.

[0062] Example 3 A composition A composition comprising docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in a weight ratio of 2:1:0.1.

[0063] Example 4 A composition A composition comprising docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in a weight ratio of 1.5:0.8:0.55.

[0064] Example 5 A composition A composition comprising docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine, wherein the weight ratio of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine is 2.5:2.2:0.55.

[0065] Comparative Example 1: A composition A composition comprising docosahexaenoic acid and 3-sialic acid lactose in a weight ratio of 2:2.05.

[0066] Comparative Example 2: A composition A composition comprising docosahexaenoic acid and phosphatidylserine in a weight ratio of 2:2.05.

[0067] Comparative Example 3: A composition A composition comprising docosahexaenoic acid, 6-sialyl lactose, and phosphatidylserine in a weight ratio of 2:1.5:0.55.

[0068] Comparative Example 4: A composition A composition comprising docosahexaenoic acid, 3-sialyl lactose, and γ-aminobutyric acid, wherein the weight ratio of docosahexaenoic acid, 3-sialyl lactose, and γ-aminobutyric acid is 2:1.5:0.55.

[0069] Experimental Example 1: Effect of the composition on improving sleep status in sleep-deprived mice 1.1 Animal Experiment Design The animals were divided into 14 treatment groups, with n=6 animals in each group, and received the following interventions: (1) Normal group (CON group): Normal feeding; (2) Sleep deprivation group (SD group): Sleep deprivation; (3) Docosahexaenoic acid group (DHA group): sleep deprivation + oral gavage of 200 mg / kg / day of DHA; (4) 3-Sialolactose group (3'-SL group): sleep deprivation + gavage 200mg / kg / day 3'-SL; (5) Phosphatidylserine group (PS group): sleep deprivation + gavage administration of 200 mg / kg / day PS; (6) Example 1 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 1; (7) Example 2 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 2; (8) Example 3 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 3; (9) Example 4 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 4; (10) Example 5 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 5; (11) Comparative Example 1: Sleep deprivation + oral gavage of 200 mg / kg / day, the same composition as Comparative Example 1; (12) Comparative Example 2: Sleep deprivation + oral gavage of 200 mg / kg / day, the same composition as Comparative Example 2; (13) Comparative Example 3: Sleep deprivation + oral gavage of 200 mg / kg / day, the same composition as Comparative Example 3; (14) Comparative Example 4: Sleep deprivation + oral gavage of 200 mg / kg / day, the same composition as Comparative Example 4; The chronic sleep deprivation (SD) protocol was implemented using an automated sleep deprivation system. Mice were placed in a transparent enclosure equipped with an automated rotating rod that alternated between clockwise and counterclockwise rotation at a speed of 5-8 rpm to induce sleep deprivation. During the 4-week deprivation period, mice were allowed free movement for 12 hours per day (ZT0-8, ZT20-24), with the SD protocol applied for the remaining time. Within the deprivation system, mice had free access to food and water. Researchers could observe the mice's activity within the deprivation chamber from outside the enclosure. The experimental design is as follows: Figure 1 As shown.

[0070] 1.2 Effect of the composition on improving sleep status in sleep-deprived mice Fifteen minutes after the last administration, mice in each group were intraperitoneally injected with sodium pentobarbital at a dose of 45 mg / kg. The criterion for sleep was the duration of loss of righting reflex ≥1 minute within 30 minutes. Sleep latency and sleep duration were recorded simultaneously. The sleep latency and sleep duration of the mice were observed and recorded.

[0071] Sleep latency = time to enter sleep state - time to inject sodium pentobarbital; Sleep duration = Sleep termination time - Time to enter sleep state.

[0072] In the pentobarbital sodium-induced sleep experiment ( Figure 2 Compared with the normal group, the sleep deprivation group showed a significant increase in sleep latency and a significant decrease in sleep duration; compared with the model group, the sleep deprivation groups in Examples 1-5 showed a significant decrease in sleep latency and a significant improvement in sleep duration. This indicates that the composition provided by the present invention can effectively prolong the writing time of mice and improve sleep maintenance problems caused by sleep deprivation.

[0073] Experimental Example 2: The regulatory effect of the composition on sleep deprivation-induced neurodevelopmental disorders in young mice. 2.1 Animal Experiment Design The animals were divided into 3 treatment groups, with n=6 animals in each group: (1) Normal diet group (CON group): Normal feeding; (2) Sleep deprivation group (SD group): Sleep deprivation; (3) Example 1 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 1; The chronic sleep deprivation (SD) protocol was implemented using an automated sleep deprivation system. Mice were placed in a transparent enclosure equipped with an automated rotating rod that alternated between clockwise and counterclockwise rotation at a speed of 5–8 r / min to induce sleep deprivation. During the 4-week deprivation period, mice were allowed free movement for 12 hours per day (ZT0–8, ZT20–24), with the SD protocol applied for the remaining time. Within the deprivation system, mice had free access to food and water. Researchers could observe the mice's activity within the deprivation chamber from outside the enclosure. The experimental design is as follows: Figure 1 As shown.

[0074] 2.2 Mouse memory behavior test The Barnesmaze was provided by Shanghai Xinsoft Co., Ltd. Before the experiment, mice were acclimatized to the dark box for 30 seconds, then placed inside an opaque cylinder at the center of a truncated cone for 30 seconds. After the cylinder was opened, they were allowed to explore freely for 3 minutes, and the latency to enter the dark box was recorded. If a mouse failed to enter within the time limit, it was manually guided, and the latency was recorded as 180 seconds. After each test, the platform holes were randomly rotated 1-3 positions, while the target box's location remained fixed. The dark box was removed the day before the test, and the mice were allowed 180 seconds of spatial exploration. The spatial memory ability of the mice was assessed by the time it took to find the target hole and the exploration latency.

[0075] The Barnes maze test assessed the spatial memory ability of mice. The results of five consecutive days of orientation and navigation training showed that ( Figure 3 In the Barnes maze test, there was no significant difference in the total movement distance, indicating that the motor abilities were basically the same. The exploration time of the target area holes in the Example 1 group was significantly increased compared with the model group (P<0.05). The results showed that the intervention of the composition in Example 1 could significantly improve the spatial memory ability of SD mice and alleviate the cognitive impairment induced by sleep deprivation in mice.

[0076] 2.3 Detection of anxiety-like behaviors in mice Mice were placed in the center of a motion monitoring box (40 cm × 40 cm × 40 cm), and their movement trajectories were recorded over 5 minutes using the Supermaze animal behavior analysis system. The total distance traveled by the mice and the percentage of distance and time spent in the central area were calculated. Before each experiment, all mice were allowed to acclimatize for 5 minutes in a clean, un-bedding cage. After each experiment, the enclosure was thoroughly cleaned and wiped with a 75% ethanol solution to eliminate any residual odors.

[0077] The open field test is used to evaluate the spontaneous activity ability of mice. The experimental results are as follows: Figure 4 As shown, there was no significant difference in the total movement distance of mice in the open field among the groups. The intervention with the composition of Example 1 reduced the stationary time of SD mice in the open field (p<0.01). These results indicate that the intervention with the composition of the present invention has no significant effect on the spontaneous movement ability of mice. Compared with the control group, the movement distance of the model group mice in the central region was significantly decreased (P<0.05), while the movement distance of the Example 1 group in the central region was significantly increased compared with the model group (P<0.01). These results indicate that sleep deprivation can induce anxiety-like behavior, and the anxiety-like behavior induced by sleep deprivation was significantly improved in the mice of Example 1 group.

[0078] Experimental Example 3: The effect of the composition on improving concentration 3.1 Preparation and Basic Training of the 5C-CPT Testing Apparatus The test device uses a 5-hole control box, with five holes arranged in an arc on the rear wall. Each hole contains an infrared beam sensor (for recording the mouse's hole detection response) and a cue light (stimulus source). The box also includes a food reward dispenser (dispensing standard mouse food pellets when the mouse makes a correct response). The testing device is connected to a data acquisition system that automatically records the mouse's reaction time, hit rate, false alarm rate, and other indicators.

[0079] Before the experiment officially began, all mice underwent 70 5C-CPT pre-training sessions to gradually familiarize them with the testing procedure. Initially, a simple selection task was used, activating only a cue light with one hole, training mice to detect holes to obtain food rewards when the cue light was lit. As training progressed, the process gradually transitioned to using a complete 5-hole array, introducing both target stimuli (one-hole cue light lit) and non-target stimuli (all 5-hole cue lights lit simultaneously) during training. This taught mice to detect holes when the target stimulus appeared and to inhibit detection behavior when non-target stimuli appeared.

[0080] After each training session, data such as the mouse's d' value (an indicator of alertness), omission rate, and reaction time (RT) were acquired using a data acquisition system. When the mouse's d' value, omission rate, and RT remained stable for three consecutive days (with fluctuations not exceeding 10%), and the hit rate of the target stimulus was ≥80% and the correct rejection rate of the non-target stimulus was ≥80%, the mouse was considered to have achieved a stable training effect and could proceed to the formal experimental stage.

[0081] 3.2 Grouping of Animal Experiments Eighteen pre-trained mice with stable 5C-CPT performance were stratified and randomly divided into groups based on baseline d' value, hit rate, and miss rate to ensure no significant difference in baseline performance among the groups (p>0.05 through statistical analysis). The mice were ultimately divided into three groups of six each, as follows: (1) Normal diet group (CON group): Normal feeding; (2) Sleep deprivation group (SD group): Sleep deprivation; (3) Example 1 group: sleep deprivation + gavage 200mg / kg / day of the composition of Example 1; The chronic sleep deprivation (SD) protocol was implemented using an automated sleep deprivation system. Mice were placed in a transparent enclosure equipped with an automated rotating rod that alternated between clockwise and counterclockwise rotation at a speed of 5–8 r / min to induce sleep deprivation. During the 4-week deprivation period, mice were allowed free movement for 12 hours per day (ZT0–8, ZT20–24), with the SD protocol applied for the remaining time. Within the deprivation system, mice had free access to food and water. Researchers could observe the mice's activity within the deprivation chamber from outside the enclosure. The experimental design is as follows: Figure 1 As shown.

[0082] 3.3 5C-CPT Test Fifteen minutes after the last administration, mice in all groups underwent the 5C-CPT test. The duration of each test was set to 30-60 minutes based on the mice's endurance and compliance to ensure sufficient valid test data were obtained. The mice were placed in the adaptation area of ​​the 5C-CPT test chamber and allowed to adapt for 5 minutes before the test program was started.

[0083] During the test, stimuli were presented according to preset parameters: the target stimulus was the cuelight of a random hole lit up (lasting 100ms), and the mouse had to probe the hole within 1 second after the stimulus disappeared. If successful, a food reward was delivered; the non-target stimulus was the cuelight of 5 holes lit up simultaneously (lasting 100ms), and the mouse had to suppress the probing behavior. If it did not probe, it would receive a food reward 1 second after the stimulus disappeared.

[0084] The data acquisition system connected to the testing device automatically records various indicators for each mouse during the test, including the number of hits, the number of misses, the number of correct rejections, the number of false alarms, and the reaction time. The relevant indicators are calculated using the following formula: Hit rate (%) = (Number of hits / (Number of hits + Number of misses)) × 100%; False Message Rate (%) = (Number of false messages / (Number of false messages + Number of correct rejections)) × 100%; Omission rate (%) = (Number of omissions / Total number of trials) × 100%; Accuracy (%) = (Number of hits + Number of correct rejections) / Total number of trials × 100%; Alertness index (d') = z (hit rate) - z (false alarm rate); where z is the quantile function of the standard normal distribution.

[0085] Experimental results are as follows Figure 5 As shown, compared with the normal diet group, the hit rate and accuracy of mice in the sleep deprivation group were significantly reduced, while the false alarm rate, omission rate, and alertness index were significantly increased. The hit rate and accuracy of mice in Example 1 group were significantly improved, while the false alarm rate, omission rate, and alertness index were all reduced. This indicates that the composition of the present invention can effectively improve target response defects caused by sleep deprivation, restore the mice's correct inhibition ability to non-target stimuli, enhance basic alertness, improve attention deficits caused by sleep deprivation, and exert an attention-improving effect.

[0086] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition, characterized in that, The composition consists of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine.

2. The composition according to claim 1, characterized in that, The weight ratio of docosahexaenoic acid, 3-sialyl lactose and phosphatidylserine in the composition is 1.5-2.5:0.8-2.2:0.1-1.

3. The composition according to claim 2, characterized in that, The weight ratio of docosahexaenoic acid, 3-sialyl lactose, and phosphatidylserine in the composition is 2:1-2:0.1-1.

4. A method for preparing the composition according to any one of claims 1-3, characterized in that, The preparation method includes mixing docosahexaenoic acid, 3-sialyl lactose and phosphatidylserine evenly to obtain the composition.

5. A food product, characterized in that, The food product includes the composition according to any one of claims 1-3.

6. The food product according to claim 5, characterized in that, The food products also include nutritionally acceptable additives.

7. The food product according to claim 6, characterized in that, The nutritional additives include any one or more of the following: dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

8. A health product, characterized in that, The health product includes the composition according to any one of claims 1-3.

9. The health product according to claim 8, characterized in that, The health products mentioned also include any one or more of the following: plant extracts, animal extracts, vitamins, bioactive peptides, enzymes, acids, polysaccharides, or minerals.

10. The food product according to any one of claims 5-7 or the health product according to any one of claims 7-9, characterized in that, The dosage forms of the food or health products mentioned include solid dosage forms, semi-solid dosage forms, or liquid dosage forms.

11. The use of the composition according to any one of claims 1-3 in the preparation of a product, characterized in that, The products mentioned include any one or more of the following: (1) Foods, health products, or medicines that help improve memory; (2) Medications for the prevention, treatment, or adjunctive treatment of insomnia; (3) Medications for the prevention, treatment, or adjunctive treatment of anxiety; (4) Medications for regulating neurodevelopmental disorders; (5) Medicines that protect brain health; (6) Medications to improve concentration.

12. A medicine, characterized in that, The pharmaceutical product includes the composition according to any one of claims 1-3.

13. The pharmaceutical product according to claim 12, characterized in that, The dosage forms of the medicine include any one or more of the following: tablets, pills, powders, suspensions, gels, emulsions, creams, granules, capsules, suppositories, injections, sprays, and injections.

14. The pharmaceutical product according to claim 12, characterized in that, The medicine also includes pharmaceutically acceptable excipients.

15. The pharmaceutical product according to claim 14, characterized in that, The pharmaceutically acceptable excipients include one or more of the following: wetting agents, emulsifiers, preservatives, antioxidants, buffers, diluents, lubricants, solutes, suspending agents, solubilizers, thickeners, stabilizers, sweeteners, and flavorings.

Images